drugset / Trial / NCT00006350
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Treatment
Summary
RATIONALE: Monoclonal antibodies such as daclizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation from a brother or sister may be effective treatment for hematologic cancer. Sometimes the transplanted cells can be rejected by the body's tissue. Mycophenolate mofetil, tacrolimus, and donor white blood cells may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of mycophenolate mofetil, tacrolimus, daclizumab, and donor peripheral stem cell transplantation in treating patients who have hematologic cancer.
Timeline
- Start
- 2000-01
- Primary completion
- 2001-11
- Completion
- 2001-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclizumab | Monoclonal antibody | — | Intravenous |
| Subject | Mycophenolate Mofetil | Small molecule | — | Oral |
| Subject | Tacrolimus | Small molecule | — | Oral |
| Subject | therapeutic allogeneic lymphocytes | Cell therapy | — | Intravenous |